PTOTAC HSD17B13 degrader 1
PTOTAC HSD17B13 degrader 1 is a HSD17B13 PROTAC degrader with a DC50 of 0.11 nM. HSD17B13 is a liver lipid droplet-associated medium-chain dehydrogenase/retinol dehydrogenase. PTOTAC HSD17B13 degrader 1 can be used in liver cancer research.
(Pink: HSD17B13 ligand (HY-159662); Blue: Cereblon ligand (HY-159660); Black: linker (HY-W003696)).
For research use only. We do not sell to patients.
- CAS No.: 3046195-01-8
- Formula: C45H45ClF3N7O5
- Molecular Weight:856.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
HSD17B13[1]
In Vitro
PTOTAC HSD17B13 degrader 1 (Example 1) can achieve sub-nanomolar level HSD17β13 degradation in Huh7 cells, with a DC50 of 0.11 nM and a Dmax of 87%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 3046195-01-8
-
Molecular Weight 856.33
-
Formula C45H45ClF3N7O5
-
SMILES
O=C1N(C2C(NC(CC2)=O)=O)C3=CC=C(CCCN4CC5=CC(C6=CC7=NN([C@@H]8CC[C@H](CC8)CNC(C9=C(C(F)=C(C(F)=C9)O)F)=O)C=C7C=C6)=CC=C5C4)C=C3N1C.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)